Ohm20 You might be correct with regards to the fact that "a

New Post Public Reply Private Reply Replies (1) Message Board
carpediemdriver ohm20 #94060
599
Ohm20 You might be correct with regards to the fact that "a sphingosine kinase-2 inhibitor is not better than a janus kinase inhibitor and puts Opaganib on level with Baractnib, and Japan did shot down the initial application for Favipiravir in Covid-19. but it is my understanding that the trail for approval of both Opaganib and Avigan(R)/Reeqonus(TM) (favipiravir) as a potential oral therapy for patients with mild-to-moderate COVID-19 is still on-going, in fact I am not making a statement based on the possible success or failure of any of these molecules. My statement was FYI (for your information ) in direct response to Post made On: 06/19/2021 1:46:26 PM Posted By: swordman
"There's also no diagnostic test, no specific treatment, no pill to take. And while research is ongoing, there aren't large, peer-reviewed, gold-standard clinical trials yet either. "Read More: https://investorshangout.com/post/view?id=616...z6yM2IkG6P

My response was only to provided with fact based information/evidene in an effort to inform the poster ... in order to help keep the integrity of the information being provided on this form. It is important that poster continues to put forth their best effort to only post accurate information to the best of their knowledge, and if the information is incorrect it should be corrected. I do not like when posters make blanket statements regarding information that may be incorrect it’s important that the information being shared on this message board be as accurate as possible and backed by factual information, unless given as ones opinion but not as fact and if it is an opinion that it should be stated as such (IMOP) and not be interpreted as fact when it is not a factor but just ones opinion.

It is also important that we understand the competitive landscape that we are in relation to other molecules that are targeting the indications (Covid-19) that we are seeking approval for in an effort to have a realistic perspective on the advantages and disadvantages that we might face in our effort to seek approval and accurately value our investment in the molecule and the value of indication that we are seeking approval for.

Regardless I am hoping for more positive information regarding LL next week please have a great father day.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

BexBack Offers Revolutionary 100x Leverage Crypto Trading

Updated Category News Views 136

Transform Your Crypto Trading Experience with BexBack In the rapidly evolving world of cryptocurrency trading, events can significantly impact market dynamics. BexBack Exchange, a prominent platform, is at the forefront of change by introducing a no KYC, 100x leverage trading option. This innovative structure comes alongside an enticing double deposit bonus and a $50...

Continue Reading
Landmark Bancorp Plans Earnings Call for Q3 2024 Results

Updated Category News Views 56

Landmark Bancorp to Host Conference Call for Earnings Discussion Landmark Bancorp, Inc. (Nasdaq: LARK) is set to release its earnings report for the third quarter of 2024 following market closure on a Wednesday. This upcoming announcement is highly anticipated by investors and stakeholders who keep a keen eye on the company's performance and insights. Details of the...

Continue Reading
AT&T Presents Final Offer to CWA Union Amidst Strike

Updated Category News Views 66

AT&T's New Proposal to CWA Union Telecom giant AT&T (NYSE: T) has taken a significant step by presenting its final offer to the Communications Workers of America (CWA) bargaining committee. This development occurs amidst ongoing negotiations and a strike involving over 17,000 employees, including technicians and customer service representatives. Details of the Final Offer...

Continue Reading
Aspen Aerogels Shows Adaptability Amid Changing Market Trends

Updated Category News Views 133

Aspen Aerogels Demonstrates Resilience in Financial Results Recent awards indicate growth potential & strategic advancements in energy solutions. Aspen Aerogels, Inc. (NYSE: ASPN), a company known for its pioneering efforts in sustainability and electrification technology, has released its financial results for the third quarter of 2025. The company's adaptability in...

Continue Reading
Great Elm Capital Corp. Updates on Third Quarter Earnings Call

Updated Category News Views 124

Great Elm Capital Corp. Announces Third Quarter Earnings Release Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC) has exciting news for investors and stakeholders. They have scheduled the release of their third-quarter financial results following the close of trading on a Tuesday in early November. This briefing brings together key stakeholders to...

Continue Reading